Document:

EX-10.7

 Exhibit 10.7 

Keros Therapeutics, Inc 
 December 14, 2015

 Jasbir S. Seehra, Ph.D. 
 [***] 

Dear Jasbir: 
 It is my pleasure to confirm the offer to you for
the position of CEO at Keros Therapeutics, Inc. (the “Company”), beginning on December 15, 2015 (the “Commencement Date”). 
 This
letter and accompanying enclosures will summarize important details about your employment. Also, enclosed is information about our current benefits which are provided to the employees at Company. 

Compensation: Your salary will be four hundred and ten thousand US Dollars 410,000 per year and will be payable in 24 bimonthly installments in
accordance with the Company’s standard payroll practices and procedures, and which will be subject to all applicable tax reporting and withholding. 

Additional Benefits: You will also be entitled to vision, health and dental insurance, at rates which shall be agreed with you upon the
commencement of your employment. You will also be eligible for enrollment in the 401k Plan which will be reviewed with you when you begin your employment. In the event that the Company does not have such vision, health, dental or 401K plans in place
during your first month of employment, the Company will reimburse you for 100% of the cost of COBRA insurance coverage, as well as for costs of dental treatments otherwise covered by your current dental plan. You will use reasonable efforts to
minimize such dental treatment costs during the first month of employment. 
 Vacation Time: You will be entitled to 4 weeks annual vacation
plus all statutory US holidays. 
 Term of Employment: It is important for you to understand that you will be an employee “at will”.
This means that you will have the right to terminate your employment relationship with Company at any time for any reason. Similarly, Company will have the right to terminate its employment relationship with you at any time for any reason.
Termination for convenience by either party will be subject to 30 days prior notice. This letter should not be construed as a guarantee of any particularly compensation, benefits or other terms or conditions of employment for any particular period
of time. Your employment and this letter will be governed by the laws of Massachusetts, USA. Any modification or change in your at will employment status may only occur by way of a written amendment signed by you and the Company. 

Company Agreement and Employment Eligibility: The offer of employment is contingent upon your signing Company’s Employee Non-Competition, Non-Solicitation, Confidentiality and Assignment Agreement (“Non-compete Agreement”) and 1-9 Employment Verification Form. The former is enclosed with this letter, and the latter will be furnished to you on your first date of employment. You will be required to submit documentation that establishes
identity and employment eligibility in accordance with the US Immigration and Naturalization requirements. 
 In addition, by signing below, you represent
that you are not bound by any employment contract, restrictive covenant or other restriction preventing or limiting you from entering into employment with or carrying out your responsibilities for the Company, or which is in any way inconsistent
with the terms of this letter. You also agree that you will not disclose to anyone at the Company, or use in the course of your employment at the Company, any confidential information or trade secrets belonging to any former employer or to any other
entity. 
 You may indicate your acceptance of this offer and the Non-Compete Agreement by signing on the
appropriate space and returning signed copies to my attention at the Company by December 15, 2015. 

 Keros Therapeutics, Inc 

 

 We are excited about the opportunity of working with you. Please contact me if you have any questions or need
more information. 
 Sincerely, 
 I accept the above terms of
employment as stated: 
  

					
	 /s/ Jasbir S. Seehra
	 		 	12/15/2015        
	Jasbir S. Seehra, Ph.	 		 	Date
		 		 	

 Enclosures: 
  

	 	•	 	 Non-Competition,
Non-Solicitation, Confidentiality and Assignment 

  

	 	•	 	 1-9 Employment Verification FormEX-10.8

 Exhibit 10.8 

KEROS THERAPEUTICS, INC 

[***] 
 April 20, 2016 

Jennifer L. Lachey 
 [***] 

Re:    Employment by Keros Therapeutics, Inc. 

Dear Jenn: 
 Keros Therapeutics, Inc. (the “Company”)
is pleased to confirm its offer to employ you as VP, Biology and Pharmacology, reporting to the CEO, Jasbir Seehra. Your effective date of hire as a regular, full-time employee (the “Start Date”) will be May 9, 2016. 

Your compensation for this position will be at the rate of $230,000 per year payable bi-weekly in accordance with the
Company’s normal pay schedule. All payments are subject to legally required tax withholdings. 
 Subject to the approval of the Board of Directors of
the Company (the “Board”), in connection with the commencement of your employment, the Board will grant you an option to purchase 150,000 shares of the Company’s common stock (the “Option”). The Option will be granted
following the commencement of your employment. The exercise price of the Option will be determined by the BOD at the next meeting following your employment. The Option will be subject to the terms and conditions of the Company’s then-current
stock option plan and form of stock option agreement. These options will vest as follows: one quarter of the shares (37,500) will vest on the first anniversary of the Start Date, and following that,
1/16th of the shares (9,375) will vest on a quarterly basis, in arrears. Vesting is contingent on your continued full-time employment with the Company. 

You will be eligible to participate in the Company’s Medical and Dental Insurance Programs 401(k) Plan. You will accrue 15 paid vacation days each year
for the first 5 years of service, 3 Personal days and receive 12 paid holidays annually in accordance with the company holiday schedule (remainder of 2016 schedule attached). 

It is understood that you are an “at-will” employee. You are not being offered employment for a definite
period of time, and either you or the Company may terminate the employment relationship at any time and for any reason, with or without cause or prior notice and without additional compensation to you. 

 Enclosed for your review is a “Non-Solicitation,
Confidentiality and Assignment Agreement” (the “Agreement”). This offer of employment is conditioned on your willingness to sign and abide by the terms of the Agreement. 

In making this offer, the Company understands, and in accepting it you represent that you are not under any obligation to any former employer or any person or
entity which would prevent, limit, or impair in any way the performance by you of your duties as an employee of the Company. 
 The Immigration Reform and
Control Act requires employers to verify the employment eligibility and identity of new employees. You will be required to complete a Form 1-9 which will be provided to you before the Start Date. Please bring
the appropriate documents listed on that form with you when you report for work. We will not be able to employ you if you fail to comply with this requirement. 

This letter agreement and the Agreement referenced above constitute the complete agreement between you and the Company, contain all of the terms of your
employment with the Company and supersede any prior agreements, representations or understandings (whether written, oral or implied) between you and the Company. This letter agreement may not be amended or modified, except by an express written
agreement signed by both you and a duly authorized officer of the Company, although your job duties, title, reporting relationship, compensation and benefits may change from time to time, at the Company’s option. 

Please indicate your acceptance of this offer by signing and returning the enclosed copy of this letter no later than Tuesday April 26, 2016. 

You may sign, scan, and email the letter to seehrajgverizon.net. We look forward to your joining the Company and are pleased that you will be working with us.

 Very truly yours, 
 /s/ Jasbir S. Seehra 

Jasbir S. Seehra, Ph.D. 
 Chief Executive Officer 

Keros Therapeutics, Inc. 
 Accepted and Agreed: 

 

	
	/s/ Jennifer L. Lachey    22 Apr 2016

 Jennifer L. Lachey, Ph.D.EX-10.9

 Exhibit 10.9 
  

 
 August 20, 2019 
 Re:
Employment by Keros Therapeutics, Inc.  
 Dear Claudia: 

Keros Therapeutics, Inc. (the “Company”) is pleased to confirm its offer to employ you as a Chief Medical Officer (CMO), reporting to Jasbir Seehra,
Chief Executive Officer (CEO). Your effective date of hire as a regular, full-time employee (the “Start Date”) will be September 16, 2019. 

Your base salary will be at the rate of $15,208.33 per, SEMI-MONTHLY, per pay period (which equates to an annualized rate of $365,000.00), subject to tax and
other withholdings as required by law. Such base salary may be adjusted from time to time in accordance with normal business practice and in the sole discretion of the Company. 

You will also be paid a $30,000 signing bonus in the pay cycle following commencement of your employment. By your acceptance of this offer of employment, you
agree to repay to the Company the amount of any signing bonus received by you if you voluntarily terminate your employment prior to the 2nd anniversary of the first day of your employment by the Company. Any amount which becomes repayable by you by
virtue of this provision will be repayable in full, without any pro rate deduction for days spent by you in the Company’s employment. 
 In addition,
you will be eligible to be considered for an incentive bonus for each fiscal year of the Company. The bonus (if any) will be awarded based on objective or subjective criteria established by the Company’s Chief Executive Officer and approved by
the Company’s Board of Directors. Your target bonus will be equal to 30% of your annual base salary. Any bonus for the fiscal year in which your employment begins will be prorated, based on the number of days you are employed by the Company
during that fiscal year. Any bonus for a fiscal year will be paid within 2 months after the close of that fiscal year, but only if you are still employed by the Company at the time of payment. The determinations of the Company’s Board of
Directors with respect to your bonus will be final and binding. 
 In connection with the commencement of your employment, the Company will recommend that
the Board of Directors grant you a stock option (the “Option”) to purchase 224,000 shares of the Company’s Common Stock with an exercise price equal to the fair market value on the date of the grant. The Option will be subject to the
terms and conditions of the Company’s then-current stock option plan and form of stock option agreement. These options will vest as follows: one quarter of the shares (56,000) will vest on the first anniversary of the Start Date, and following
that, 1/16th of the shares will vest on a quarterly basis, in arrears. Vesting is contingent on your continued employment with the Company. 

 You will be eligible to participate in the Company’s Medical and Dental Insurance Programs, including
having the option to contribute into a Flexible Spending Account. Keros Therapeutics will also reimburse the first 50% of the Medical Plan deductible. In addition, you will be eligible to participate in the Keros 401(k) Plan. You will accrue 15 paid
vacation days each year, 3 personal days and receive 12 paid holidays annually in accordance with the company holiday schedule. 
 It is understood that you
are an “at-will” employee. You are not being offered employment for a definite period of time, and either you or the Company may terminate the employment relationship at any time and for any reason,
with or without cause or prior notice and without additional compensation to you. 
 Enclosed for your review is your Invention Assignment, Non-Disclosure, and Business Protection Agreement (the “Agreement”). This offer of employment is conditioned on your willingness to sign and abide by the terms of the Agreement. 

In making this offer, the Company understands, and in accepting it you represent that you are not under any obligation to any former employer or any person or
entity which would prevent, limit, or impair in any way the performance by you of your duties as an employee of the Company. 
 The Immigration Reform and
Control Act requires employers to verify the employment eligibility and identity of new employees. You will be required to complete a Form I-9 which will be provided to you before the Start Date. Please bring
the appropriate documents listed on that form with you when you report for work. We will not be able to employ you if you fail to comply with this requirement. 

This letter agreement and the Agreement referenced above constitute the complete agreement between you and the Company, contain all of the terms of your
employment with the Company and supersede any prior agreements, representations or understandings (whether written, oral or implied) between you and the Company. This letter agreement may not be amended or modified, except by an express written
agreement signed by both you and a duly authorized officer of the Company, although your job duties, title, reporting relationship, compensation and benefits may change from time to time, at the Company’s option. 

Please indicate your acceptance of this offer by signing and returning the enclosed copy of this letter no later than August 23rd, 2019. 
 You may sign, scan, and email the letter to annita@kerostx.com. We look forward to your joining
the Company and are pleased that you will be working with us. 
 Very truly yours, 

	
	
	/s/ Jasbir S. Seehra
	Jasbir S. Seehra, Ph.D.
	Chief Executive Officer
	Keros Therapeutics, Inc.

 Accepted and Agreed: 

	
	
	/s/ Claudia Ordonez
	Claudia Ordonez, M.D.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00306-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00306-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00306-of-00352.parquet"}]]